One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
  • Report Library
  • Who Trust Us
  • inquiry@market.us
  • +1 718 618 4351 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
  • Report Library
  • Who Trust Us
Home » Cystic-Fibrosis Therapeutics Market
Cystic-Fibrosis Therapeutics Market
Cystic-Fibrosis Therapeutics Market
Published date: Feb 2022 •Formats:
Request Sample Schedule a Call
  • Home » Cystic-Fibrosis Therapeutics Market

Global Cystic-Fibrosis Therapeutics Market By Drug Class (CFTR modulators, Mucolytic, Pancreatic enzyme supplements and Bronchodilators), By Route of Administration (Oral drugs and Inhaled drugs), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

  • Published date: Feb 2022
  • Report ID: 78573
  • Number of Pages: 245
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Sample
  • Cystic-Fibrosis Therapeutics Market Overview

    In 2021, The Global Cystic-Fibrosis Therapeutics Market was valued at USD 6,836.4 Million. It is expected to grow at a CAGR of 13.94% from 2023-2032 due to its rising prevalence and treatment rates.

    The Market will be driven by a number of key factors, including a rise in R&D funding from both public and private organizations, the rise in initiatives by non-profit organizations, and promising reimbursement policies. The Cystic Fibrosis Foundation published data showing that the prevalence of these hereditary conditions is increasing. The number of patients with Cystic Fibrosis in the United States was 58,983 Million in 2020, compared to 47,366 in 2019. The demand for effective and efficient CF therapies is increasing year on year due to an increase in patients. Cystic Fibrosis Transmembrane Conductance Regulator, (CFTR), bronchodilator drugs, and mucolytic drugs are some of the approved drug classes.

     

    Global Cystic-Fibrosis Therapeutics Scope:

    Drug Class Analysis:

    Based on drug class, the market can be divided into pancreatic enzyme supplements, mucolytics, and bronchodilators. The main consideration for CF treatment is to maintain lung function, control respiratory infection, clear the airways of saliva, and manage the nutritive therapy. Kalydeco, the initial CFTR modulator, was introduced in the U.S. in 2019. It was still the only CFTR moderator drug available in 2020.
    The launch of Orkambi, a new drug that targets CFTR modulators, was responsible for the highest share of revenue in 2021, at 47.3%. This drug corrects the purpose of the faulty protein produced by the CF gene. These drug class straight treats the original cause. The main factor contributing to its share is its product introduced in 2015. CFTR modulators are also expected to see profitable growth at a rate of 24.2% during the prediction period.

    Cystic Fibrosis Therapeutics Market analysis

    Route of Administration Analysis

    The Market can be divided into two types of routes depending on how it is administered. With a nearly 63.7% share, the oral route was the most popular. This is due to its ease of use and convenience. The key factor driving demand for oral drugs in emerging countries is the growing awareness of their benefits, including CFTR modulators as well as pancreatic enzyme supplementation. Orally administered therapeutics include CFTR modulators like KALYDECO or ORKAMBI, as well as pancreatic enzyme supplements such as PERTZYE and Creon/Zenpep. The oral drug Market will be driven by the high commercial obtainability and large demand for these drugs to delicacy CF. According to the U.S. Patient Registry 2020, hypertonic Saline was prescribed to 11.5% of children aged 0-3 years and 42.9% of children aged 3-3 years. One of the main reasons for the growing request for oral drug formulation is the increasing incidence of CF in newborn babies.

    The Market is expected to grow due to an increase in clinical trials that expand the patient base. The segment is also expected to grow at a profit of 20.1% during the forecast era. This segment will also see a growing number of public and private players invest in it.

    Маrkеt Ѕеgmеntѕ:

    Drug Class

    • CFTR modulators
    • Mucolytics
    • Pancreatic enzyme supplements
    • Bronchodilators

    Route of Administration

    • Oral drugs
    • Inhaled drugs

    Market Dynamics

    Market growth will be driven by a growing number of drug compositions being developed by the major players. This Market is driven by a growing number of clinical trials that aim to increase the patient base and expand the drug portfolio. Market growth is expected to be driven by increasing R&D activities. The pipelined drugs include (VX-445 + Tezacaftor + Ivacaftor); QR-010; AZD-55634; and, POL-6014.
    One of the key factors behind the surge in demand is the presence of many non-profit organizations like Cystic Fibrosis Worldwide and Cystic Fibrosis Foundation, Cystic Fibrosis Canada, and South African Cystic Fibrosis Trust. These organizations invest huge sums of money to help develop and research new therapies for CF.

    Regional Analysis

    The Market can be divided by region into Europe, North America and the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America was the most lucrative region with USD 5,396.4 million. North America is the most affected region for CF, with most people living with it being Caucasian. Cystic Fibrosis Canada and CF Foundation are two of the reasons why CF is so prevalent.
    The Asia Pacific will be the fastest-growing section, with an 18.8% growth rate. Despite the fact that CF is less common in the Asia Pacific due to the lack of Nation-specific registries and underdiagnoses, this Market will see a rise in consciousness about CF disorders and treatment options over the forecast period. The Market will be boosted by the region’s economic development and improved healthcare facilities over the prediction period.

    The Market will be boosted by the awareness of healthcare professionals and patients about the new therapeutic options available in the market. Currently, there are not many CF-specific drugs available. However, product launches and approvals in this Market are expected to drive growth.

    Cystic-Fibrosis Therapeutics Market Regional Share

    Кеу Regions and Countries covered іn thе rероrt:

    • North America
      • US
      • Canada
      • Mexico
    • Europe
      • Germany
      • UK
      • France
      • Italy
      • Russia
      • Spain
      • Rest of Europe
    • APAC
      • China
      • Japan
      • South Korea
      • India
      • Rest of Asia-Pacific
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • MEA
      • GCC
      • South Africa
      • Israel
      • Rest of MEA

    Market Share & Key Players Analysis:

    Cystic Fibrosis is treated by a variety of products, and the key players are involved in their development. Strategic measures include investing in R&D to outperform the competition. Vertex Pharmaceuticals Inc., AbbVie, Inc., Gilead, Novartis AG, F. Hoffmann-La Roche Ltd, AIT (Advanced Inhalation Therapies); Merck & Co. Alaxia Pharmaceutical Industries Ltd., Inc., Alcresta Therapeutics, Inc., Allergan, and AstraZeneca are the key players in this Market

    Cystic-Fibrosis Therapeutics Market Company Analysis

    Market Key Players:

    • Hoffmann-La Roche Ltd.
    • Gilead
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Vertex Pharmaceuticals Inc.
    • Alcresta Therapeutics
    • Merck & Co. Inc.
    • AIT (Advanced Inhalation Therapies)
    • Other Key Players

    For the Cystic-Fibrosis Therapeutics Market research study, the following years have been considered to estimate the market size:

    AttributeReport Details

    Historical Years

    2016-2020

    Base Year

    2021

    Estimated Year

    2022

    Short Term Projection Year

    2028

    Projected Year

    2023

    Long Term Projection Year

    2032

    Report Coverage

    Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.

    Regional Scope

    North America, Europe, Asia-Pacific, South America, Middle East & Africa

    Country Scope

    United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa

    Share
    Tweet
    Share
    Pin
    0 Shares

    Frequently Asked Questions (FAQ)

    What is the Cystic-Fibrosis Therapeutics Market size in 2021?

    The Cystic-Fibrosis Therapeutics Market size is $ 6,836.4 million in 2021.

    What is the CAGR for the Cystic-Fibrosis Therapeutics Market?

    The Cystic-Fibrosis Therapeutics Market is expected to grow at a CAGR of 13.94 % during 2023-2032.

    What are the segments covered in the Cystic-Fibrosis Therapeutics Market report?

    Market .US has segmented the Global Cystic-Fibrosis Therapeutics Market Value (US$ Mn) Analysis by Region, 2022 Market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By Drug Class, Market has been further divided into Sheet and strips, Plates. Route of Administration.

    Who are the key players in the Cystic-Fibrosis Therapeutics Market?

    F. Hoffmann-La Roche Ltd., Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Alcresta Therapeutics, are the key vendors in the Cystic-Fibrosis Therapeutics Market

    Which region is more attractive for vendors in the Cystic-Fibrosis Therapeutics Market?

    North America will register the highest revenue share of 67% among the other regions. Therefore, the Cystic-Fibrosis Therapeutics Market in APAC is expected to garner significant business opportunities for the vendors during the forecast period.

    What are the key Markets for Cystic-Fibrosis Therapeutics?

    Key Markets for Cystic-Fibrosis Therapeutics are Japan, India and China

    Which segment has the largest share in the Cystic-Fibrosis Therapeutics?

    In the Cystic-Fibrosis Therapeutics Market, vendors should focus on grabbing business opportunities from the CFTR modulators segment as it accounted for the largest Market share in the base year.

    Cystic-Fibrosis Therapeutics Market
    Cystic-Fibrosis Therapeutics Market
    Published date: Feb 2022
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Hoffmann-La Roche Ltd.
    • GileadTeva Pharmaceutical Industries Ltd.
    • Novartis AG Company Profile
    • Vertex Pharmaceuticals Inc.
    • Alcresta Therapeutics
    • Merck & Co. Inc.
    • AIT (Advanced Inhalation Therapies)
    • Other Key Players
  • settingsSettings

Related Reports

  • Croscarmellose Sodium Market
  • Assistive Listening Devices Market
  • Single-Cell Multiomics Маrkеt
  • Gas Engines Market
  • Blood Cancer Drugs Market
  • Cefazolin Sodium Market

Our Clients

  • Our Clients
Inquiry Before Buying

Cystic-Fibrosis Therapeutics Market
  • 78573
  • Feb 2022
    • ★★★★★
      ★★★★★
    • (22)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
Multi User
$7,999
$3,499
USD / per unit
save 55%
Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
auto undefined
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sundanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
  • Report Library

© 2025 Market.Us. All Rights Reserved.